Senseonics Holdings, Inc. — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the provided filing text does not give separate Q4 financial results. Senseonics develops and manufactures Eversense, an implantable continuous glucose monitoring (CGM) system. Ascensia is its exclusive global commercialization partner for the current system, while Senseonics handles development and manufacturing.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Total revenue | $22.4 million | $16.4 million |
| Gross profit / margin | $3.1 million / 13.8% | $2.7 million / 16.6% |
| Operating loss | $75.6 million | $68.6 million |
| Net income (loss) | $(60.4) million | $142.1 million |
| Net cash used in operating activities | $70.2 million | $66.3 million |
| Cash, cash equivalents and marketable securities | $109.5 million | $156.3 million |
| Debt carrying amount | $41.2 million | $87.9 million |
- Revenue rose $6.0 million, or about 36.6%, attributed mainly to increased commercial activity and a full year of Eversense E3 sales; sales outside the U.S. were slightly lower.
- Cost of sales increased to $19.3 million from $13.7 million. Gross margin fell 2.8 percentage points, which management attributed mainly to sales-channel mix and higher contract manufacturing/raw-material costs.
- R&D expense increased $9.0 million to $48.8 million, primarily reflecting next-generation product investment and clinical studies. SG&A declined $1.7 million to $29.9 million.
- FY2022 net income was substantially driven by noncash fair-value gains on embedded derivatives and options. FY2023 included $15.2 million of total other income, including a $14.1 million exchange-related gain and a $6.6 million gain from derivative fair-value changes; these items make reported earnings less representative of operating performance.
- Year-end current assets were $130.0 million and current liabilities $17.3 million. The company reported an accumulated deficit of $869.3 million.
- Revenue concentration remains high: Ascensia, a related party, represented 93% of FY2023 revenue, versus 96% in FY2022. U.S. revenue was 62.8% of total, up from 45.8%.
Material changes, financing and debt
- In 2023, Senseonics repaid its $15.7 million 2023 Notes and exchanged $35.0 million of PHC Notes for a pre-funded warrant to purchase up to 68.5 million common shares. PHC also purchased a separate pre-funded warrant for $15.0 million, covering up to 15.4 million shares.
- The company exchanged up to $30.8 million principal amount of 2025 Notes for $7.5 million cash and 35.1 million newly issued common shares. Approximately $20.4 million principal remained outstanding at year-end, due January 2025.
- A Hercules senior secured term-loan facility provides up to $50.0 million. $25.0 million was funded in September 2023; a further $10.0 million was funded January 2, 2024 after year-end. The remaining $15.0 million tranche is conditional. The facility matures September 2027, bears interest at the greater of prime plus 1.40% or 9.90%, and is secured by substantially all company assets. It includes minimum-cash and revenue covenants, among other restrictions.
- Common shares issued and outstanding increased to 530.4 million at year-end from 479.6 million a year earlier. The PHC pre-funded warrants, outstanding at year-end and exercisable for a nominal price, represent substantial potential dilution.
- Operating cash use increased to $70.2 million. Investing cash inflow of $89.7 million largely reflected net sales and maturities of marketable securities, rather than operating cash generation. Financing cash inflow was $20.4 million.
Outlook, risks and other notable items
- Management said existing cash and cash equivalents and expected operating cash flows should fund anticipated needs for at least 12 months after the financial statements were issued. It also said commercialization, product development and regulatory work will require significant working capital through 2024 and beyond, and it may seek further capital.
- The company is not profitable from operations and expects additional losses. Management does not expect profitability for at least the next several years; successful adoption, reimbursement, and Ascensia’s commercial execution are central to the business outlook.
- The ENHANCE pivotal study’s adult cohort was completed and analyzed. Senseonics said it would advance a next-generation sensor platform and expected to submit to FDA in the coming weeks for a product targeting 365-day wear and once-weekly calibration. The filing also expected an FDA decision on iCGM designation in the first half of 2024. These were forward-looking expectations, not confirmed approvals in the filing.
- In February 2024, after the reporting period, the company announced expanded Medicare coverage for Eversense E3 for insulin users and certain non-insulin users with problematic hypoglycemia. The first Medicare administrative contractor expansion took effect February 25, 2024; other expansions were expected.
- Key risks include dependence on Ascensia (93% of revenue), limited commercial scale, reimbursement and insertion-procedure payment uncertainty, competition from larger CGM companies, supplier and contract-manufacturing concentration, regulatory and clinical-development uncertainty, continued cash burn, debt covenants and repayment obligations, and potential dilution.
- The 2025 Notes and new secured loan impose restrictions and default provisions; a default could accelerate debt. Remaining 2025 Notes mature in January 2025, while the secured facility has a 2027 maturity.
- A False Claims Act qui tam case concerning marketing practices was dismissed, and the Fifth Circuit affirmed the dismissal on February 28, 2024. The filing reported no other material legal proceedings and no litigation contingencies deemed probable and reasonably estimable at year-end.
- KPMG issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the filing included no auditor attestation of internal controls because of the company’s smaller-reporting-company exemption.
Important facts for investors to verify
- Progress in Eversense E3 adoption, patient retention, Ascensia sales execution, and the company’s ability to convert covered lives into reimbursed sales.
- Current status and timing of the 365-day product submission and iCGM designation, and the clinical and regulatory evidence supporting those milestones.
- Cash burn and runway against management’s stated 12-month funding assessment; availability and conditions for the remaining Hercules tranche.
- Debt covenant compliance, the January 2025 2025 Notes maturity, and the full cost and repayment schedule of secured borrowings.
- Potential dilution from PHC warrants, Series B preferred stock, equity compensation and any future equity or ATM issuance.
- Whether lower gross margins, manufacturing costs, reimbursement rates, or reliance on related-party Ascensia revenue change materially.